NDC 0069-1029 – Xeljanz
Tofacitinib Citrate 1 mg/mL · Solution · Oral
Product NDC0069-1029
Product details
- Brand name
- Xeljanz
- Generic name
- Tofacitinib
- Labeler
- Pfizer Laboratories Div Pfizer Inc
- Dosage form
- Solution
- Route
- Oral
- Marketing category
- NDA · NDA213082
- Marketed since
- February 8, 2021
- Listing expires
- December 31, 2027
- Pharmacologic class
- Janus Kinase Inhibitor
Active ingredients
- Tofacitinib Citrate 1 mg/mL
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 0069-1029-02 | 1 BOTTLE in 1 CARTON (0069-1029-02) / 240 mL in 1 BOTTLE (0069-1029-01) | Feb 8, 2021 |
Other Xeljanz products
- 63539-029 Tofacitinib Citrate 1 mg/mL · Solution · U.S. Pharmaceuticals
- 0069-0501 Tofacitinib Citrate 11 mg/1 · Tablet, Film Coated, Extended Release · Pfizer Laboratories Div Pfizer Inc
- 0069-0502 Tofacitinib Citrate 22 mg/1 · Tablet, Film Coated, Extended Release · Pfizer Laboratories Div Pfizer Inc
- 0069-1001 Tofacitinib Citrate 5 mg/1 · Tablet, Film Coated · Pfizer Laboratories Div Pfizer Inc
- 0069-1002 Tofacitinib Citrate 10 mg/1 · Tablet, Film Coated · Pfizer Laboratories Div Pfizer Inc
- 63539-012 Tofacitinib Citrate 5 mg/1 · Tablet, Film Coated · U.S. Pharmaceuticals
- 63539-016 Tofacitinib Citrate 10 mg/1 · Tablet, Film Coated · U.S. Pharmaceuticals
- 63539-501 Tofacitinib Citrate 11 mg/1 · Tablet, Extended Release · U.S. Pharmaceuticals
- 63539-502 Tofacitinib Citrate 22 mg/1 · Tablet, Extended Release · U.S. Pharmaceuticals